More than 30 women die of breast cancer every day in the UK, but today an 8-year study will offer hope to the thousands of women fighting against this killer disease.  The study conducted by ATAC shows that the drug anastrozole is the only treatment of it's kind to be significantly better than tamoxifen in preventing tumours from returning to breast cancer sufferers. 

If breast cancer returns, the consequences are much more likely to be fatal. Therefore, preventing breast cancer recurring is fundamental to saving lives and by prescribing anastrozole from the start this can achieved.  The trial showed that women who take anastrozole were 24% less likely to have their cancer come back, compared with those taking tamoxifen.

This body of research is one of the world's largest and longest-running studies in postmenopausal women with hormone receptor positive (HR+) early breast cancer. These landmark results show that even four years after a woman's treatment ends, the protective effect of anastrozole in reducing the risk of HR+, early breast cancer from returning continues to increase. 

A recent global survey showed that over 70% of physicians believe that telling a patient her breast cancer has returned is worse than giving a diagnosis of early breast cancer.  Recurrence, whether it is in the same breast, the opposite breast or elsewhere on the body means the cancer is more likely to be incurable. It is therefore essential for both patients and their doctors to be absolutely certain that they are on a best possible therapy from the very beginning.

Click here to watch the video: mms://groovyg.edgestreams.net/groovyg/clients/Markettiers4dc/webchats/11638/11638_astra1webchats_278k.wmv

For more information visit:  www.ATAC100.com